Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

@article{Johnston2001RandomisedTO,
  title={Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack},
  author={Dennis Johnston},
  journal={The Lancet},
  year={2001},
  volume={358},
  pages={1033-1041}
}
  • D. Johnston
  • Published 29 September 2001
  • Medicine
  • The Lancet

Figures from this paper

Effects of a perindopril-based blood-pressure-lowering regimen in patients with previous stroke or transient ischaemic attack (progress). How do the results affect practice in Pakistan?

The aim of this particular study was to determine the effects of a flexible blood pressure lowering regimen on the risk of stroke recurrence and other major vascular events in patients who had a history of stroke or Transient ischaemic attack.

The Perindopril Protection Against Recurrent Stroke Study (PROGRESS)

Current evidence is now strong for clinicians to consider blood pressure-lowering therapy as pivotal in the prevention of stroke, especially in patients with a known history of cerebrovascular disease, irrespective of blood pressure levels.

Efficacy and Tolerability of Fixed-Dose Combination Perindopril/Indapamide in Hypertensive Patients with a History of Stroke or Transient Ischemic Attack: PICASSO Trial

This study suggests that fixed combination perindopril 10 mg/indapamide 2.5 mg is an effective and well-tolerated treatment for patients with a history of stroke or transient ischemic attack, and decreases in SBP/DBP were statistically significant in patients with all grades of hypertension.

Poststroke patients: implications for the cardiologist

It is demonstrated that a perindopril-based regimen is of clinical importance for preventing stroke and cardiac events in both hypertensive and non-hypertensive patients with stroke or transient ischaemic attack.

Recurrent Stroke Prevention: Diuretic and Angiotensin-Converting Enzyme Inhibitors (ACEIs)—The PROGRESS Trial.

The rationale and design of the Perindopril Protection Against Secondary Stroke Study (PROGRESS) was published in 1996 (J Hypertens Suppl. 1996;14(6):S47–51), while recruitment had already commenced

Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?

The treatment benefit in EUROPA cannot be fully explained by baseline BP or BP reduction with perindopril, and other mechanisms including direct anti-atherosclerotic effects of ACE inhibition may play a role.

Control of blood pressure after stroke.

Acornerstone of primary stroke prevention is built on treating “hypertension” in asymptomatic subjects who are usually at low or medium vascular risk, dogma based on the results of numerous

Secondary prevention of stroke by blood pressure-lowering treatment

Blood pressure-lowering treatment is one of the most effective and generalizable strategies for secondary prevention of stroke and an angiotensin II-receptor blocker may provide an alternative regimen in patients who do not tolerate an ACE inhibitor, especially in combination with a diuretic.

Incidence of recurrent stroke in primary care during preventive treatment based on perindopril with or without indapamide.

Perindopril +/- indapamide-based prevention may be effective in reducing risk of recurrent stroke, in the setting of day-to-day clinical practice and among patients with different demographic and clinical characteristics than the PROGRESS population.
...

References

SHOWING 1-10 OF 19 REFERENCES

PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee.

  • Medicine
    Journal of hypertension
  • 1999
The successful completion of recruitment and current indicators of statistical power suggest that the Perindopril Protection Against Recurrent Stroke Study should achieve its primary aim on schedule.

Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS

  • L. Hansson
  • Medicine
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension
  • 1996
The primary objective of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) is to determine the effects of blood pressure reduction on stroke risk in patients with a history of cerebrovascular disease.

Blood pressure lowering for the secondary prevention of myocardial infarction and stroke.

Questions about the safety of BP reduction for patients with preexisting cardiovascular disease have been raised following observations of J- and U-shaped associations between BP levels and the risks of recurrent myocardial infarction and stroke.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.

Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation

A meta-analysis of all currently available trials to further characterize the comparative efficacy and safety of antithrombotic therapy for the prevention of stroke in patients with atrial fibrillation is presented.

Blood pressure and risk of stroke in patients with cerebrovascular disease

There is widespread clinical uncertainty about lowering blood pressure in patients with ischaemic cerebrovascular disease, and concern has arisen partly from reports of a J shaped association between blood pressure and recurrent stroke in these patients.